Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed infiltrating carcinoma of the breast~  * Unresected clinical stage T1c, T2, T3, or T4 lesion, any N~* Newly diagnosed disease~  * Diagnostic mammogram and an ultrasound of the affected breast within 3 months before study entry~ * Mammogram of the contralateral breast within 6 months before study entry~* Clinically measurable disease~* Hormone receptor status:~  * Immunohistochemical staining for estrogen and progesterone and HER2/neu receptors must be obtained on initial diagnostic material~PATIENT CHARACTERISTICS:~Age~* 18 and over~Sex~* Female~Menopausal status~* Not specified~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 8 g/dL~Hepatic~* Bilirubin no greater than 1.5 times normal~Renal~* Creatinine no greater than 1.5 times normal~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No medical condition that would put the patient at unnecessary risk of potentially serious complications during study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy for current breast cancer~Endocrine therapy~* At least 1 month since prior tamoxifen or raloxifene for breast cancer prevention~* No prior endocrine therapy for current breast cancer~Radiotherapy~* No prior radiotherapy for current breast cancer~Surgery~* Not specified

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel (Type: EXPERIMENTAL): Neoadjuvant therapy with docetaxel (IV, 100 mg/m2, every 14 days with growth factor support with pegfilgrastim) for a total of 4 cycles prior to conventional surgery for breast cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).